19. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dovitinib or everolimus (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection).